期刊文献+

卡托普利和缬沙坦对兔动脉粥样硬化心肌CRP表达的影响 被引量:1

The effects of captopril and valsartan on the expression of myocardial C-reactive protein in rabbit atherosclerotic myocardium
下载PDF
导出
摘要 目的探讨卡托普利和缬沙坦从不同水平阻断血管紧张素Ⅱ(AngⅡ)后对心肌C反应蛋白(CRP)表达的影响。方法30只新西兰白兔随机分为四组(:A)高脂饮食组(、B)高脂饮食加卡托普利组(、C)高脂饮食加缬沙坦组(、D)对照组。喂饲10周后,放射免疫法测定血浆AngⅡ含量,取心肌和肝脏用免疫组化方法测定CRP的表达。结果A组心肌CRP表达较D组明显升高(P<0.005)。与A组相比,B组和C组心肌CRP表达显著降低(P<0.05,P<0.025),与D组相比,差异无统计学意义。剔除C组数据后,血浆AngⅡ水平与心肌局部CRP表达存在显著相关性(rs=0.804,P<0.0001)。肝脏CRP表达两两组间差异无统计学意义(P>0.05)。结论AngⅡ与心肌局部组织CRP的表达有显著的相关性;卡托普利和缬沙坦可降低心肌局部CRP的表达,差异无统计学意义。 Objective To observe the effects of captopril and valsartan on decreasing the expression of C-reactive protein (CRP) in rabbits atherosclerotic myocardium. Methods Thirty male New Zealand white rabbits were divided into four groups randomly : (A) cholesterol feeded group, ( B ) cholesterol + captopril-treated group, (C) cholesterol+valsartan-treated group and (D) control group. After 10 weeks, plasma angiotensin Ⅱ (Ang Ⅱ ) level was evaluated by radioimmunoassay. The heart and liver were harvested for immunohistochemistry measure of CRP. Results Compared with control group, the expression of myocardial CRP in A group increased significantly (P〈0.005). The levels of myocardial CRP in group B and group C was lower than that in group A (P〈0.05, P〈0.025 respectively). There were no difference between group B and group C with control group. The expression of myocardial CRP in group B and group C were identical. After eliminating the data of group C, the expression of myocardial CRP was correlated positively with AngⅡ level of plasma. There was no difference in expression of hepatic CRP among the four groups. Conclusion Plasma Ang Ⅱ correlated positvely with the expression of myocardial CRP. Captopril and valsartan could reduce myocardial CRP. There was no difference in the effects on reducing myocardial CRP between captopril and valsartan. Ang Ⅱ influenced more on myocardial CRP than on hepatic CRP.
出处 《中国心血管病研究》 CAS 2006年第8期614-616,共3页 Chinese Journal of Cardiovascular Research
基金 山西省资助回国留学人员科研项目(200531)
关键词 心肌 动脉硬化 C反应蛋白质 血管紧张素Ⅱ Myocardium Atherosclerosis C-reactive protein AngiotensinⅡ
  • 相关文献

参考文献10

  • 1[1]Brasier AR,Recinos Ⅲ A,Eledrisi MS.Vascular inflammation and the renin-angiotensin system.Arterioscler Thromb Vasc Biol,2002,22:1257-1266.
  • 2[2]Yasojima K,Schwab C,McGeer EG,et al.Generation of C-reactive protein and complement components in atherosclerotic plaques.Am J Pathol,2001,158:1039-1051.
  • 3[3]Kobayashi S,Inoue N,Ohashi Y,et al.Interaction of oxidative stress and inflammatory response in coronary plaque instability.Arterioscler Thromb Vasc Biol,2003,23:1398-1404.
  • 4鹿育萨,雷新宇,邸捷,黄淑田,李建民.卡托普利、缬沙坦对兔动脉粥样硬化斑块的干预作用[J].中华内科杂志,2005,44(6):425-427. 被引量:9
  • 5[5]Strawn WB,Chappell MC,Dean RH,et al.Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia.Circulation,2000,101:1586-1593.
  • 6[6]Pastore L,Tessitore A,Martinotti S,et al.Angiotensin Ⅱ stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo.Circulation,1999,100:1646-1652.
  • 7[7]Ruiz-Ortega M,Lorenzo O,Rupérez M,et al.Angiotensin Ⅱ activates nuclear transcription factor κB through AT1 and AT2 receptors in cultured vascular smooth muscle cells.Circ Res,2000,86:1266-1272.
  • 8[8]Shieffer B,Schieffer E,Hilfiker-Kleiner D,et al.Expression of angiotensin Ⅱ and interleukin 6 in human coronary atherosclerotic plaques.Circulation,2000,101:1372-1378.
  • 9[9]Burke AP,Tracy RP,Kolodgie F,et al.Elevated C-reactive protein values and atherosclerosis in sudden coronary death.Circulation,2002,105:2019-2023.
  • 10[10]Nijmeijer R,Lagrand WK,Lubbers YTP,et al.C-reactive protein activates complement in infarcted human myocardium.Am J Pathol,2003,163:269-275.

二级参考文献5

  • 1Weiss D, Sorescu D, Taylor WR. Angiotensin Ⅱ and atherosclerosis. Am J Cardiol,2001,87(8A):25C-32C.
  • 2Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation, 1996,94:2756-2767.
  • 3Neri Serneri GG, Boddi M, Poggesi L, et al. Activation of cardiac renin-angiotensin system in unstable angina. J Am Coll Cardiol,2001,38:49-55.
  • 4Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000,342:145-153.
  • 5Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. J Hypertens Suppl, 1996,14:S41-S45.

共引文献8

同被引文献15

  • 1朱洁,王雨生,张金山,张鹏,王海燕,赵炜.缺氧对培养人视网膜色素上皮细胞线粒体酶活性的影响[J].眼科新进展,2005,25(2):105-108. 被引量:8
  • 2苏敬东,李士骏,赵浩亮.咖啡因预防家兔胆囊结石形成的研究[J].中华实验外科杂志,1994,11(1):27-28. 被引量:11
  • 3Austin MA. Epidemiology of hypertriglgceridemia and cardiovas- cular disease. Am J Cardiol, 1999,83 : 13F-16F.
  • 4El-Sayyad HL, Abou-El-Naga AM, Gadallah AA, et al. Protective effects of Allium sativum against defects of hypercholesterolemia on pregnant rats and their offspring. Int J Clin Exp Med ,2010,3 : 152- 163.
  • 5Watts GF, Castelluceio C, Rice-Evans C,et al. Plasma eoenzyme Q ( ubiquinone ) concentrations in patients treated with simvastatin. J Clin Pathol, 1993,46 : 1055-1057.
  • 6Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther,1995,57 : 62-66.
  • 7De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol,1996,42:333-337.
  • 8Molyneux SL, Young JM, Florkowski CM, et al. Coenzyme Q10 : is there a clinical role and a case for measurement? . Clin Biochem Rev,2008 ,29 :71-82.
  • 9Wolff AA, Rotmensch HH, Stanley WC, et al. Metabolic approaches to the treat ment of ischemic heart disease : the clinicians'perspective. Heart Fail Rev, 2002, 7 : 187-203.
  • 10Lopaschuk GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? . Cot on Artery Dis, 2001, 12: S8-S11.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部